TNF inhibitors

Question 1

Infliximab inhibits membrane and soluble TNFa

Answer 1

T

Question 2

Infliximab is of fully human origin

Answer 2

F
76% human
25% mouse

Question 3

Adalimumab is an anti TNFa IgG

Answer 3

T

Question 4

Infliximab half life 7 days

Answer 4

T

Question 5

Development of anti drug antibodies are rare in Etanercept and Adalimumab

Answer 5

T

Question 6

Psoriasis involved skin has decreased TNF-a compared to non lesional skin

Answer 6

False

More

Question 7

Etanercept, infliximab and Adalimumab are Cat B

Answer 7

t

Question 8

Etanercept is a dimeric fully human antibody

Answer 8

T

Question 9

Concurrent administration of Etanercept , Adalimumab and infliximab with anakinra (IL-1 receptor antagonist) is a relative contraindication

Answer 9

False

Absolute contraindication

Question 10

Etanercept does not influence levels of warfarin (Cyp2C9 pathway) or digoxin

Answer 10

T

Question 11

MTX can decrease the clearance of adalimumab by 44%

Answer 11

T

Question 12

Etanercept can be used in active Hepc

Answer 12

T

Question 13

Concomitant use of TNF inh with IL-1 antagonists leads to increased risk of haematologic malignancies

Answer 13

F

Increased risk of serious infection

Question 14

Increased risk of active tb infection with Etanercept > I & A

Answer 14

F
Other way around
I&a have higher rates than the fusion protein Etanercept

Question 15

Inflimxiba contraindicated in CHF at doses above 5mg/kg

Answer 15

T

Question 16

Concomitant admin of MTX w TNF inhibitors may increase incidence of auto drug Ab

Answer 16

False

Decrease

Question 17

Increased risk of active tb infection with Etanercept > I & A

Answer 17

F
Other way around
I&a have higher rates than the fusion protein Etanercept

Question 18

Inflimxiba contraindicated in CHF at doses above 5mg/kg

Answer 18

T